|Bid||112.17 x 800|
|Ask||125.00 x 800|
|Day's Range||115.18 - 120.07|
|52 Week Range||63.00 - 140.91|
|Beta (3Y Monthly)||1.24|
|PE Ratio (TTM)||33.02|
|Earnings Date||May 6, 2019 - May 10, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||134.30|
Today we will run through one way of estimating the intrinsic value of Amedisys, Inc. (NASDAQ:AMED) by taking the foreast future cash flows of the company and discounting them back to today's value. I will be using the Discoun...
Driven by Medidata's (MDSO) standardized clinical data storehouse, and operating on its pioneering platform, Acorn AI is set to become one of the premier AI companies in the field of life sciences.
To fortify its product portfolio, Hologic (HOLX) is working on innovations and product introductions. On this front, Cynosure's R&D pipeline stays robust.
Amedisys, Inc. (AMED), announced today that it will report results for the first quarter ended March 31, 2019, after the market closes on April 30, 2019. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on May 1, 2019. To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (877) 524-8416 (Toll-Free) or (412) 902-1028 (Toll).
The outcomes of the study demonstrates that patients on TDD along with CMM witnessed some major benefits compared to those on CMM alone.
Zacks.com featured expert Kevin Matras highlights: Medifast, Foot Locker, Amedisys, Comfort Systems and CarGurus
Zacks.com featured expert Kevin Matras highlights: WellCare Health Plans, Domtar, Amedysis, Fastenal and DMC Global
Resmed's (RMD) Brightree ReSupply is a scalable and automated solution that comprises live-agent inbound and outbound calls for more private interaction with patients and email reminder capabilities.
This joint venture marks Walgreens' (WBA) commitment toward enabling access to affordable healthcare and creating neighborhood health destinations.
Before investing blindly in a stock exhibiting solid growth traits, one should consider the extent of its leverage in order to avoid falling into debt traps.
DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, rising expenses remain a dampener.
The outcomes of the study, conducted by Medtronic (MDT), demonstrates that patients on TDD along with CMM witnessed some major benefits compared to those on CMM alone.
Walgreens Boots (WBA) currently endeavors to redress certain areas of operational weakness and reinforces its managerial competence to drive operating efficiency with a resolute focus.
Medtronic's (MDT) Guardian Connect system can now be accessed via a Blue Cross and Blue Shield of Minnesota member's pharmacy benefit.
Amedisys Inc NASDAQ/NGS:AMEDView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for AMED with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold AMED had net inflows of $2.24 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The regulatory go-ahead is in line with Bio-Rad's (BIO) strategy of strengthening in the transfusion medicine market of the United States.
Intersect ENT (XENT) recently finishes the ENCORE Study, which is a small 50-patient open label program, designed to evaluate the safety of the repeat use of SINUVA.
Per Natus Medical (BABY), this deal is strategically aligned with its business as besides concentrating on its core products, this sell-off will lead to planned investment in the high-growth markets.
Medtronic's (MDT) latest data is expected to boost top-line contributions from the HeartWare HVAD System within the CRHF suite.
The primary goal of the study was to assess the safety and efficacy of Orthofix's (OFX) M6-C artificial cervical disc in comparison to ACDF treatment.
The Analytics arm, launched by ResMed (RMD) unit Brightree, provides workflow insights and facilitates KPI tracking plus peer benchmarking without the users having to amass the data themselves.